Y-mAbs Therapeutics (YMAB) Short Interest Ratio & Short Volume $10.54 -0.32 (-2.95%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Y-mAbs Therapeutics Short Interest DataY-mAbs Therapeutics (YMAB) has a short interest of 4.01 million shares, representing 10.84% of the float (the number of shares available for trading by the public). This marks a -5.65% decrease in short interest from the previous month. The short interest ratio (days to cover) is 15.0, indicating that it would take 15.0 days of the average trading volume of 280,054 shares to cover all short positions.Current Short Interest4,010,000 sharesPrevious Short Interest4,250,000 sharesChange Vs. Previous Month-5.65%Dollar Volume Sold Short$58.19 millionShort Interest Ratio15.0 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares44,790,000 sharesFloat Size37,000,000 sharesShort Percent of Float10.84%Today's Trading Volume236,780 sharesAverage Trading Volume280,054 sharesToday's Volume Vs. Average85% Short Selling Y-mAbs Therapeutics? Sign up to receive the latest short interest report for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartYMAB Short Interest Over TimeYMAB Days to Cover Over TimeYMAB Percentage of Float Shorted Over Time Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Y-mAbs Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20244,010,000 shares $58.19 million -5.7%10.8%15 $14.51 10/15/20244,250,000 shares $60.78 million +1.9%11.5%16.8 $14.30 9/30/20244,170,000 shares $54.84 million +3.5%11.3%16 $13.15 9/15/20244,030,000 shares $55.37 million -3.8%10.9%13.9 $13.74 8/31/20244,190,000 shares $59.96 million -12.7%11.4%15 $14.31 8/15/20244,800,000 shares $58.61 million +3.0%13.0%16.9 $12.21 Get the Latest News and Ratings for YMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20244,660,000 shares $57.22 million +9.9%12.9%14.8 $12.28 7/15/20244,240,000 shares $55.04 million +18.1%11.7%12.5 $12.98 6/30/20243,590,000 shares $43.37 million -1.9%9.9%10.1 $12.08 6/15/20243,660,000 shares $43.59 million +7.3%10.1%10.5 $11.91 5/31/20243,410,000 shares $41.26 million -10.0%9.4%9.3 $12.10 5/15/20243,790,000 shares $46.16 million +52.8%9.9%10.3 $12.18 4/30/20242,480,000 shares $37.72 million +6.4%7.5%6.3 $15.21 4/15/20242,330,000 shares $34.74 million +4.0%7.0%5.9 $14.91 3/31/20242,240,000 shares $36.42 million +6.7%6.8%5.3 $16.26 3/15/20242,100,000 shares $30.87 million -3.2%6.4%5.3 $14.70 2/29/20242,170,000 shares $36.24 million -1.4%6.6%5.6 $16.70 2/15/20242,200,000 shares $35.20 million -2.2%6.7%6.2 $16.00 1/31/20242,250,000 shares $28.78 million +5.6%6.8%7.3 $12.79 1/15/20242,130,000 shares $20.55 million -7.8%6.4%8.3 $9.65 12/31/20232,310,000 shares $15.75 million +6.9%6.9%11.3 $6.82 12/15/20232,160,000 shares $14.32 million -13.3%6.5%10.6 $6.63 11/30/20232,490,000 shares $15.46 million -2.4%7.4%13.7 $6.21 11/15/20232,550,000 shares $13.39 million +2.0%7.6%14.9 $5.25 10/31/20232,500,000 shares $13.35 million -4.2%7.6%13.7 $5.34 10/15/20232,610,000 shares $13.83 million -2.6%7.9%13.6 $5.30 9/30/20232,680,000 shares $14.61 million -2.9%8.1%14.9 $5.45 9/15/20232,760,000 shares $13.77 million +6.2%8.4%14.6 $4.99 8/31/20232,600,000 shares $13.18 million -17.2%7.9%11.9 $5.07 8/15/20233,140,000 shares $17.90 million +52.4%9.5%12.8 $5.70 7/31/20232,060,000 shares $12.55 million +6.7%6.1%7 $6.09 7/15/20231,930,000 shares $13.68 million +7.2%5.8%6.3 $7.09 6/30/20231,800,000 shares $12.22 million +2.3%5.5%5.1 $6.79 6/15/20231,760,000 shares $14.10 million +6.7%5.3%2.4 $8.01 5/31/20231,650,000 shares $13.41 million -8.3%5.0%2.3 $8.13 5/15/20231,800,000 shares $18.50 million -2.7%5.5%2.4 $10.28 4/30/20231,850,000 shares $11.08 million +3.4%5.6%2.6 $5.99 4/15/20231,790,000 shares $11.71 million -28.4%5.4%2.6 $6.54 3/31/20232,500,000 shares $12.53 million +26.9%7.6%3.7 $5.01 3/15/20231,970,000 shares $6.64 million +10.7%5.6%6.3 $3.37New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 2/28/20231,780,000 shares $6.76 million -3.3%5.0%4.7 $3.80 2/15/20231,840,000 shares $7.91 million -5.2%5.2%4.7 $4.30 1/31/20231,940,000 shares $8.71 million +1.0%5.5%4 $4.49 1/15/20231,920,000 shares $9.16 million -0.5%5.5%2.8 $4.77 12/30/20221,930,000 shares $9.42 million +14.2%5.5%2.8 $4.88 12/15/20221,690,000 shares $8.75 million -1.7%4.8%2.4 $5.18 11/30/20221,720,000 shares $7.69 million +17.0%4.9%2.7 $4.47 11/15/20221,470,000 shares $6.56 million -52.3%4.2%2.4 $4.46 10/31/20223,080,000 shares $11.12 million -17.0%8.7%5.8 $3.61 10/15/20223,710,000 shares $53.50 million -1.6%10.5%13.5 $14.42 9/30/20223,770,000 shares $54.36 million -2.3%10.7%13.5 $14.42 9/15/20223,860,000 shares $55.97 million +2.1%10.9%13.6 $14.50 8/31/20223,780,000 shares $60.78 million +1.1%10.7%11.5 $16.08 8/15/20223,740,000 shares $70.39 million +5.4%10.6%10.5 $18.82 7/31/20223,550,000 shares $55.34 million +2.9%10.1%8.3 $15.59 7/15/20223,450,000 shares $57.41 million -4.7%9.8%7.3 $16.64 6/30/20223,620,000 shares $54.77 million -9.7%10.3%7.6 $15.13 6/15/20224,010,000 shares $46.36 million -4.3%11.4%8.8 $11.56 5/31/20224,190,000 shares $52.12 million +1.2%11.9%9 $12.44 5/15/20224,140,000 shares $42.64 million +43.3%11.8%8.6 $10.30 4/30/20222,890,000 shares $24.28 million -1.7%8.2%3.9 $8.40 4/15/20222,940,000 shares $37.69 million +3.9%8.4%3.9 $12.82 3/31/20222,830,000 shares $33.62 million +25.2%8.1%3.7 $11.88 3/15/20222,260,000 shares $19.66 million -5.8%6.4%3 $8.70 2/28/20222,400,000 shares $21.86 million -6.6%6.8%3.4 $9.11 2/15/20222,570,000 shares $20.82 million +31.1%7.3%3.7 $8.10 1/31/20221,960,000 shares $19.38 million No Change5.7%5 $9.89 1/15/20221,960,000 shares $23.76 million +2.1%5.7%6.8 $12.12 12/31/20211,920,000 shares $31.12 million -6.8%5.6%8.5 $16.21 12/15/20212,060,000 shares $34.20 million -7.2%6.0%9.6 $16.60 11/30/20212,220,000 shares $37.92 million -7.9%6.5%11.4 $17.08 11/15/20212,410,000 shares $52.78 million -9.1%7.0%13.2 $21.90 10/29/20212,650,000 shares $65.08 million +7.7%7.7%14.3 $24.56 10/15/20212,460,000 shares $65.63 million +1.2%7.2%13.2 $26.68 9/30/20212,430,000 shares $69.35 million -10.3%7.1%11.8 $28.54 9/15/20212,710,000 shares $91.73 million +2.3%7.9%12.6 $33.85 8/31/20212,650,000 shares $81.57 million -12.0%7.7%11.1 $30.78 8/13/20213,010,000 shares $87.56 million +2.7%8.8%11.9 $29.09 7/30/20212,930,000 shares $96.98 million +4.3%8.5%11.4 $33.10 7/15/20212,810,000 shares $87.59 million -1.8%8.2%10.8 $31.17 6/30/20212,860,000 shares $96.67 million -4.4%8.4%10.6 $33.80 6/15/20212,990,000 shares $103.39 million -4.5%8.8%10.3 $34.58 5/28/20213,130,000 shares $112.15 million -3.1%9.3%10.6 $35.83 5/14/20213,230,000 shares $105.78 million +7.7%9.6%10.1 $32.75 4/30/20213,000,000 shares $89.07 million -1.6%8.9%8.9 $29.69 4/15/20213,050,000 shares $81.71 million -15.8%10.8%9.7 $26.79 3/31/20213,620,000 shares $107.08 million +27.9%12.8%11.8 $29.58 3/15/20212,830,000 shares $101.94 million -2.4%10.0%9.7 $36.02 2/26/20212,900,000 shares $97.67 million +30.0%10.7%10.9 $33.68 2/12/20212,230,000 shares $106.77 million -24.2%8.3%8.9 $47.88New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 1/29/20212,940,000 shares $125.30 million -2.7%11.7%13.2 $42.62 1/15/20213,020,000 shares $150.94 million -1.6%12.0%13.8 $49.98 12/31/20203,070,000 shares $153.53 million -12.5%12.2%15.3 $50.01 12/15/20203,510,000 shares $183.19 million +0.3%13.9%17.1 $52.19 11/30/20203,500,000 shares $168.67 million +1.7%14.0%19.1 $48.19 10/30/20203,350,000 shares $145.26 million +2.8%13.4%23 $43.36 10/15/20203,260,000 shares $129.85 million +11.6%13.2%21.6 $39.83 9/30/20202,920,000 shares $112.10 million +15.4%11.9%18.2 $38.39 9/15/20202,530,000 shares $99.61 million -0.4%10.3%14.6 $39.37 8/31/20202,540,000 shares $109.30 million -4.2%10.3%13.7 $43.03 8/14/20202,650,000 shares $103.38 million -0.8%10.8%12.2 $39.01 7/31/20202,670,000 shares $93.80 million +3.9%10.9%10.7 $35.13 7/15/20202,570,000 shares $102.34 million +2.4%10.6%10.3 $39.82 6/30/20202,510,000 shares $108.43 million +12.6%10.3%9.9 $43.20 6/15/20202,230,000 shares $93.95 million +4.7%9.2%9.3 $42.13 5/29/20202,130,000 shares $81.32 million -2.3%8.8%8 $38.18 5/15/20202,180,000 shares $84.15 million -5.6%9.0%8.4 $38.60 4/30/20202,310,000 shares $77.57 million +0.4%9.7%10.3 $33.58 4/15/20202,300,000 shares $69.09 million +14.4%9.3%10.4 $30.04 3/31/20202,010,000 shares $52.46 million +2.0%8.2%8.8 $26.10 3/13/20201,971,200 shares $57.50 million +15.3%15.6%6.3 $29.17 2/28/20201,710,000 shares $33.04 million +30.5%13.5%7.8 $19.32 2/14/20201,310,000 shares $33.08 million -3.0%5.3%6.1 $25.25 1/31/20201,350,000 shares $40.64 million -10.0%6.9%5.6 $30.10 1/15/20201,500,000 shares $49.89 million -9.1%7.7%5.3 $33.26 12/31/20191,650,000 shares $58.01 million +55.7%8.3%6 $35.16 YMAB Short Interest - Frequently Asked Questions What is Y-mAbs Therapeutics' current short interest? Short interest is the volume of Y-mAbs Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,010,000 shares of YMAB short. 10.84% of Y-mAbs Therapeutics' shares are currently sold short. Learn More on Y-mAbs Therapeutics' current short interest. What is a good short interest ratio for Y-mAbs Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. YMAB shares currently have a short interest ratio of 15.0. Learn More on Y-mAbs Therapeutics's short interest ratio. What is a good short interest percentage for Y-mAbs Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.84% of Y-mAbs Therapeutics' floating shares are currently sold short. Is Y-mAbs Therapeutics' short interest increasing or decreasing? Y-mAbs Therapeutics saw a decline in short interest during the month of October. As of October 31st, there was short interest totaling 4,010,000 shares, a decline of 5.6% from the previous total of 4,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Y-mAbs Therapeutics' float size? Y-mAbs Therapeutics currently has issued a total of 44,790,000 shares. Some of Y-mAbs Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Y-mAbs Therapeutics currently has a public float of 37,000,000 shares. How does Y-mAbs Therapeutics' short interest compare to its competitors? 10.84% of Y-mAbs Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Y-mAbs Therapeutics: Mersana Therapeutics, Inc. (7.99%), Amarin Co. plc (4.37%), Heron Therapeutics, Inc. (18.94%), Generation Bio Co. (3.40%), Aurinia Pharmaceuticals Inc. (5.13%), Evotec SE (0.08%), Harmony Biosciences Holdings, Inc. (15.15%), Disc Medicine, Inc. (10.50%), NewAmsterdam Pharma (1.61%), Tarsus Pharmaceuticals, Inc. (21.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Y-mAbs Therapeutics stock? Short selling YMAB is an investing strategy that aims to generate trading profit from Y-mAbs Therapeutics as its price is falling. YMAB shares are trading down $0.32 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Y-mAbs Therapeutics? A short squeeze for Y-mAbs Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of YMAB, which in turn drives the price of the stock up even further. How often is Y-mAbs Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including YMAB, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Mersana Therapeutics Short Interest Data Amarin Short Interest Data Heron Therapeutics Short Interest Data Generation Bio Short Interest Data Aurinia Pharmaceuticals Short Interest Data Centessa Pharmaceuticals Short Interest Data Harmony Biosciences Short Interest Data Evotec Short Interest Data Recursion Pharmaceuticals Short Interest Data Tarsus Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:YMAB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
